Sarah Hein, March Biosciences CEO
October 23, 2024 08:00 AM EDTUpdated 12:13 PM
Financing
Startups
Cell/Gene Tx

Hous­ton start­up March Bio­sciences rais­es $28M to get CAR-T in­to Phase 2

Kyle LaHucik

Senior Reporter

A nim­ble Hous­ton start­up has raised a con­cise $28.4 mil­lion Se­ries A to start a mid-stage tri­al.

The com­pa­ny, named March Bio­sciences, will en­ter Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Al­to Neu­ro­science's mid-stage tri­al miss­es pri­ma­ry end­point in de­pres­sion

Roche says it is un­de­terred by up­com­ing biosim­i­lar threat to Vabysmo

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times